KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Receivables (2018 - 2025)

Historic Receivables for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $30.7 million.

  • Aurinia Pharmaceuticals' Receivables fell 1581.37% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year decrease of 1581.37%. This contributed to the annual value of $36.5 million for FY2024, which is 5163.49% up from last year.
  • Aurinia Pharmaceuticals' Receivables amounted to $30.7 million in Q3 2025, which was down 1581.37% from $40.1 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Receivables' 5-year high stood at $41.8 million during Q3 2022, with a 5-year trough of $1.2 million in Q1 2021.
  • Its 5-year average for Receivables is $24.4 million, with a median of $24.1 million in 2023.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Receivables plummeted by 6582.17% in 2021, and later soared by 160008.33% in 2022.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' Receivables stood at $15.4 million in 2021, then dropped by 12.42% to $13.5 million in 2022, then surged by 78.44% to $24.1 million in 2023, then soared by 51.7% to $36.5 million in 2024, then fell by 15.92% to $30.7 million in 2025.
  • Its last three reported values are $30.7 million in Q3 2025, $40.1 million for Q2 2025, and $40.4 million during Q1 2025.